Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma [Yahoo! Finance]
Soligenix, Inc. (SNGX)
NASDAQ:AMEX Investor Relations:
soligenix.com/investors
Company Research
Source: Yahoo! Finance
Nov. 19, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the formation of a European Medical Advisory Board (MAB) to provide additional medical/clinical strategic guidance to the Company as it advances its confirmatory Phase 3 multicenter, double-blind, placebo-controlled study evaluating the safety and efficacy of HyBryte™ (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma (CTCL) patients with early-stage disease. This confirmatory, 18-week study is expected to enroll approximately 80 patients in the United States (U.S.) and Europe , and is targeted to begin patient enrollment by the end of 2024 with top-line results anticipated in the second half of 2026. "Stemming from the positive feedback from the European Medicines Agency (EMA) on the key design components of our c
Show less
Read more
Impact Snapshot
Event Time:
SNGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNGX alerts
High impacting Soligenix, Inc. news events
Weekly update
A roundup of the hottest topics
SNGX
News
- Cutaneous T-cell Lymphoma Market Landscape Report 2024: Comprehensive Insights About 25+ Companies and 30+ Pipeline Drugs [Yahoo! Finance]Yahoo! Finance
- Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell LymphomaPR Newswire
- Soligenix to Present at November 21st Virtual Investor Summit Microcap Event [Yahoo! Finance]Yahoo! Finance
- Soligenix to Present at November 21st Virtual Investor Summit Microcap EventAccesswire
- Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease [Yahoo! Finance]Yahoo! Finance
SNGX
Sec Filings
- 11/8/24 - Form 424B3
- 11/8/24 - Form 424B3
- 11/8/24 - Form 424B3
- SNGX's page on the SEC website